Program
pirfenidone
Also written as “Pirfenidone”, “Pirfenidone Modified-Release Tablets” and “Deupirfenidone”.
Its studies are mostly in Idiopathic Pulmonary Fibrosis · Lung Injury · Lung Diseases, Interstitial · Pulmonary Fibrosis · COVID-19, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 120 open or running | phase 4since Nov 4, 2015 | Mar 24, 2004 | none ahead |
| GNI Group | 72 open or running | phase 3since Feb 26, 2019 | Nov 18, 2014 | Dec 30, 2026phase 3 · NCT07388680 |
| PureTech | 52 open or running | phase 3since Dec 8, 2025 | Jan 21, 2020 | Nov 2029phase 3 · NCT07284602 |
| Overseas Pharmaceuticals | 30 open or running | phase 1since Aug 22, 2024 | Aug 22, 2024 | none ahead |
| beijing-kawin-technology-share-holding-co-ltd | 10 open or running | phase 2since Dec 30, 2011 | Dec 30, 2011 | none ahead |
| grupo-medifarma-s-a-de-c-v | 10 open or running | phase 3since Jul 6, 2015 | Jul 6, 2015 | none ahead |
Also a collaborator on its studies: clinipace-worldwide, novotech-australia-pty-limited, shanghai-genomics-inc and gni-eps-pharmaceuticals-inc-gni-group.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 13 studies since Mar 24, 2004.
- Mar 31, 2017Phase 2 study in Lung Diseases, InterstitialHoffmann-La Roche · NCT03099187 · 253 enrolled · Australia, Belgium, Canada and more
- Jun 26, 2017Phase 3 study in Idiopathic Pulmonary FibrosisHoffmann-La Roche · NCT03208933 · 60 enrolled · Russian Federation
- Feb 26, 20192 phase 3 studiesGNI Group · NCT03857854, NCT03856853
- Apr 2, 2019Phase 2 study in Radiation-induced Lung InjuryGNI Group · NCT03902509 · 126 enrolled · China
- Oct 10, 2019Phase 1 study in Renal InsufficiencyGNI Group · NCT04126538 · 24 enrolled · China
- Jan 21, 2020PureTech's first study: phase 2 study in LymphedemaNew to PureTechPureTech · NCT04243837 · 50 enrolled · United States, Australia
- Dec 2, 2020Phase 2 study in COVID-19PureTech · NCT04652518 · 185 enrolled · United States, Argentina, Brazil and more
- Feb 17, 2022Phase 3 study in PneumoconiosisGNI Group · NCT05288179 · 272 planned · China
- Apr 2, 2022Phase 2 study in Idiopathic Pulmonary FibrosisPureTech · NCT05321420 · 240 enrolled · United States, Argentina, Chile and more
- Aug 22, 2024Overseas Pharmaceuticals's first study: phase 1 study in Idiopathic Pulmonary FibrosisNew to Overseas PharmaceuticalsOverseas Pharmaceuticals · NCT06569381 · 18 enrolled · China
- Sep 6, 20242 phase 1 studies in Idiopathic Pulmonary FibrosisOverseas Pharmaceuticals · NCT06589921, NCT06588517
- Nov 17, 2025Phase 3 study in Radiation-induced Lung InjuryGNI Group · NCT07388680 · 298 planned · China
- Dec 8, 2025Phase 3 study in Idiopathic Pulmonary FibrosisPhase 3 reachedPureTech · NCT07284602 · 1,100 planned · United States, Canada
- Feb 19, 2026Phase 1 study in Pharmacokinetic AnalysisPureTech · NCT07456800 · 116 enrolled · United States
Ahead
- Dec 30, 2026Primary completion: phase 3 study in Radiation-induced Lung InjuryGNI Group · NCT07388680
- Nov 2029Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisPureTech · NCT07284602
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 29 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07456800Pharmacokinetic Analysis · United States | 1 | Completed | PureTech | Jan 1, 2022 | 116 |
| NCT07284602Idiopathic Pulmonary Fibrosis · United States, Canada | 3 | Recruiting | PureTech | Nov 2029 | 1,100 |
| NCT07388680Radiation-induced Lung Injury · China | 3 | Recruiting | GNI Group | Dec 30, 2026 | 298 |
| NCT06589921Idiopathic Pulmonary Fibrosis · China | 1 | Completed | Overseas Pharmaceuticals | Sep 5, 2023 | 24 |
| NCT06588517Idiopathic Pulmonary Fibrosis · China | 1 | Completed | Overseas Pharmaceuticals | Apr 19, 2024 | 12 |
| NCT06569381Idiopathic Pulmonary Fibrosis · China | 1 | Completed | Overseas Pharmaceuticals | Oct 1, 2024 | 18 |
| NCT05321420Idiopathic Pulmonary Fibrosis · United States, Argentina, Chile and more | 2 | Active, not recruiting | PureTech | Oct 15, 2024 | 240 |
| NCT05288179Pneumoconiosis · China | 3 | Recruiting | GNI Group | Sep 30, 2026 | 272 |
| NCT04652518COVID-19 · United States, Argentina, Brazil and more | 2 | Terminated | PureTech | Jun 28, 2022 | 185 |
| NCT04243837Lymphedema · United States, Australia | 2 | Terminated | PureTech | Sep 9, 2022 | 50 |
| NCT04126538Renal Insufficiency · China | 1 | UNKNOWN | GNI Group | Nov 25, 2021 | 24 |
| NCT03902509Radiation-induced Lung Injury · China | 2 | Completed | GNI Group | Dec 4, 2023 | 126 |
| NCT03857854Dermatomyositis Interstitial Lung Disease (Dm-ILD) · China | 3 | UNKNOWN | GNI Group | Feb 2021 | 152 |
| NCT03856853Systemic Sclerosis-associated Interstitial Lung Disease (Ssc-ild) · China | 3 | UNKNOWN | GNI Group | Feb 10, 2021 | 144 |
| NCT03208933Idiopathic Pulmonary Fibrosis · Russian Federation | 3 | Completed | Hoffmann-La Roche | Nov 13, 2019 | 60 |
| NCT03099187Lung Diseases, Interstitial · Australia, Belgium, Canada and more | 2 | Completed | Hoffmann-La Roche | Nov 21, 2018 | 253 |
| NCT02648048Idiopathic Pulmonary Fibrosis · United States, Germany | 1 | Completed | Hoffmann-La Roche | Nov 30, 2016 | 21 |
| NCT02598193Idiopathic Pulmonary Fibrosis · United States, Canada, Denmark and more | 4 | Completed | Hoffmann-La Roche | May 16, 2017 | 89 |
| NCT02525484Healthy Volunteer · United States | 1 | Completed | Hoffmann-La Roche | Aug 2015 | 44 |
| NCT02496182Alveolitis, Extrinsic Allergic · Mexico | 3 | UNKNOWN | grupo-medifarma-s-a-de-c-v | Jan 2016 | 60 |
| NCT02296281Radiation Pneumonitis | 2 | UNKNOWN | GNI Group | Jun 2016 | 48 |
| NCT01933334Scleroderma, Systemic · United States, Canada, Italy | 2 | Completed | Hoffmann-La Roche | Sep 2014 | 63 |
| NCT01872689Idiopathic Pulmonary Fibrosis · United States, Australia, Belgium and more | 2 | Completed | Hoffmann-La Roche | Jul 28, 2017 | 505 |
| NCT01504334Idiopathic Pulmonary Fibrosis · China | 2 | UNKNOWN | beijing-kawin-technology-share-holding-co-ltd | Nov 2012 | 80 |
| NCT01366209Idiopathic Pulmonary Fibrosis · United States | 3 | Completed | Hoffmann-La Roche | Feb 2014 | 555 |
| NCT00662038Idiopathic Pulmonary Fibrosis · United States | 3 | Completed | Hoffmann-La Roche | Feb 2016 | 1,058 |
| NCT00287729Idiopathic Pulmonary Fibrosis · United States | 3 | Completed | Hoffmann-La Roche | Nov 2008 | 344 |
| NCT00287716Idiopathic Pulmonary Fibrosis · United States | 3 | Completed | Hoffmann-La Roche | Nov 10, 2008 | 435 |
| NCT00080223Idiopathic Pulmonary Fibrosis · United States | 2 | Completed | Hoffmann-La Roche | Apr 30, 2015 | 83 |
How it is read
Names in the registry
- “Pirfenidone”, 26 entries
- “Pirfenidone Modified-Release Tablets”, 4 entries
- “Deupirfenidone”, 3 entries
- “pirfenidone capsule”, 2 entries
- “pirfenidone”, 2 entries
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 21 studies
- Lung Injury, 2 studies
- Lung Diseases, Interstitial, 2 studies
- Pulmonary Fibrosis, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.